BioAtla reports FY2022 net loss $106.5M, cash $215.5M; advances CAB-ADC and bispecific trials

BioAtla, Inc.

Net loss Q4 2022 $27.5M, full year $106.5M, vs Q4 2021 $23.4M and FY2021 $95.4M.
R&D expenses FY2022 $79.3M, up from $58.3M in FY2021, driven by clinical development.
Cash $215.5M at year-end 2022; expected to fund operations into 2025.
Cleared DLT for BA3011 dose-intensive schedule; LMS readout 2H23; UPS registrational Phase 2 start in 1H23.
FDA cleared IND for BA3182 (CAB-EpCAMxCD3 TCE); FPI Phase 1 in 1H23. BA3021 NSCLC and BA3071 Phase 2 data in 2H23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioAtla, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Period: the fourth quarter and fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 23, 2023, BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009469

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.